Drugs / CYT004-MelQbG10
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00306566 | — | melanoma | Cytos Biotechnology AG | Completed | No outcome recorded |
| Phase 1/2 | NCT00306514 | — | melanoma | Cytos Biotechnology AG | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00651703 | Apr 2008 → Dec 2009 | melanoma | Cytos Biotechnology AG | Completed | No outcome recorded |
| Phase 2 | NCT00306553 | — | melanoma | Cytos Biotechnology AG | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CYT004-MelQbG10 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00306514 ↗ |
| Modality | Vaccine | “Melan-A VLP vaccine” NCT00306553 ↗ |
| Route | Other | “CYT004-MelQbG10 intra nodal injection” NCT00651703 ↗ |